However, CCNU is administered in combination with procarbazine, a methylating agent, and vincristine, which inhibits microtubule formation, for recurrent GBM or patients who do not respond to TMZ, according to what is called the PVC regimen [53]. The gene discussed is CCNO; the disease is glioblastoma.